iShares Biotechnology ETF $IBB Stock Holdings Lifted by Richard W. Paul & Associates LLC

Richard W. Paul & Associates LLC lifted its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 8.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,289 shares of the financial services provider’s stock after acquiring an additional 560 shares during the quarter. Richard W. Paul & Associates LLC’s holdings in iShares Biotechnology ETF were worth $922,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of IBB. Citigroup Inc. raised its position in shares of iShares Biotechnology ETF by 88.5% during the first quarter. Citigroup Inc. now owns 3,208,144 shares of the financial services provider’s stock worth $410,322,000 after purchasing an additional 1,505,976 shares during the period. JPMorgan Chase & Co. increased its stake in iShares Biotechnology ETF by 74.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 833,196 shares of the financial services provider’s stock worth $105,408,000 after purchasing an additional 355,000 shares in the last quarter. Millennium Management LLC raised its holdings in iShares Biotechnology ETF by 140.8% during the 1st quarter. Millennium Management LLC now owns 41,676 shares of the financial services provider’s stock worth $5,330,000 after buying an additional 143,893 shares during the period. Jones Financial Companies Lllp lifted its stake in iShares Biotechnology ETF by 763.3% during the first quarter. Jones Financial Companies Lllp now owns 151,265 shares of the financial services provider’s stock valued at $19,347,000 after buying an additional 133,744 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC lifted its stake in iShares Biotechnology ETF by 769.9% during the second quarter. Ashton Thomas Private Wealth LLC now owns 63,691 shares of the financial services provider’s stock valued at $8,058,000 after buying an additional 56,369 shares in the last quarter. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Price Performance

iShares Biotechnology ETF stock opened at $167.52 on Friday. iShares Biotechnology ETF has a fifty-two week low of $107.43 and a fifty-two week high of $168.73. The firm’s 50 day simple moving average is $153.36 and its 200-day simple moving average is $138.34.

iShares Biotechnology ETF Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 19th. Shareholders of record on Tuesday, September 16th were given a dividend of $0.0828 per share. This represents a $0.33 annualized dividend and a yield of 0.2%. The ex-dividend date was Tuesday, September 16th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.